La ricerca è una priorità per SIFaCT e la pubblicazione del paper su una rivista scientifica di livello internazionale è il risultato finale e tangibile del lavoro svolto. Di seguito le pubblicazioni vengono suddivise secondo diversi criteri per facilitare la selezione dell’articolo di interesse prodotto dalla società scientifica.
Nel riquadro a destra puoi selezionare i seguenti 4 filtri: Anno di pubblicazione – Primo autore – Impact factor – Topic
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy
Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is Small.
The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors.
A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia.
Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials.
The QOSMOS Study: Pharmacist-Led Multicentered Observational Study on Quality of Life in Multiple Sclerosis.
Oncostability: stability of reconstituted and diluted anticancer medicines for a possible extension of use
Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy.
Experience in managing independent clinical research, the best training strategy for future clinical pharmacists: the QOSMOS project
Hospital pharmacy response to covid-19 pandemic in italy: what we learned from the first outbreak wave